FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to the study of the mouse genome, which contains in the mouse locus TNFR2 gene containing human exons 2 to 6, encoding the extracellular part of human TNFR2 binding to human TNF, with the possibility of conditionally blocking the activity of the TNFR2 gene in cells expressing cre-recombinase. A method for studying the activity of therapeutic agents that bind to human TNF, including introduction of such agents to the above-mentioned mouse, is also disclosed. The invention also relates to a method for studying the activity of therapeutic agents of agonists and antagonists binding to human TNFR2, including introduction of such agents to the above mouse.
EFFECT: invention is effective in the study of the properties of drugs used in treatment of autoimmune diseases.
4 cl, 2 tbl, 4 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE RISK OF DEVELOPING AN ISCHEMIC STROKE, TAKING INTO ACCOUNT GENETIC AND MEDIUM FACTORS | 2018 |
|
RU2679635C1 |
| HUMANIZED T-CELL MEDIATED IMMUNE RESPONSES IN NON-HUMAN ANIMALS | 2016 |
|
RU2732628C2 |
| FCγR HUMANISED MICE | 2010 |
|
RU2549695C2 |
| NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE | 2014 |
|
RU2670016C1 |
| NON-HUMAN ANIMALS HAVING A HUMANIZED PROLIFERATION-INDUCING LIGAND GENE | 2014 |
|
RU2671101C1 |
| NON-HUMAN ANIMALS HAVING HUMANIZED Fc-γ-RECEPTORS | 2015 |
|
RU2700484C2 |
| HUMANISED IL-15 ANIMALS | 2014 |
|
RU2674910C2 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAUCOMA IN INDIVIDUALS DEPENDING ON PRESENCE/ABSENCE OF COMORBIDITY OF EYES | 2014 |
|
RU2597784C2 |
| GENETICALLY MODIFIED MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES | 2012 |
|
RU2660564C2 |
| METHOD FOR PREDICTION OF RISK OF STAGE III HYPERTENSIVE DISEASE IN PATIENTS WITH HYPERTENSION WITH METABOLIC SYNDROME | 2014 |
|
RU2598745C2 |
